Peptilogics receives qualified infection disease product designation for PJI treatment

Peptilogics announced the FDA granted qualified infection disease product designation to PLG0206 for the treatment of prosthetic joint infections.

Developed utilizing the company’s engineered cationic antibiotic peptide platform, PLG0206 has been shown in a preclinical study to eliminate a variety of biofilm-associated bacteria, sterilizing implants following short exposure in a biofilm model, according to a company press release. The release noted that these results suggest that, in a clinical setting, PLG0206 may rapidly kill implant-associated biofilm bacteria.

“Researchers estimate that by 2020, more than 65,000 patients per year with prosthetic joint implants will develop [prosthetic joint infections] PJIs, resulting in over $1.6 billion in annual inpatient costs,” Sanjay Kakkar, MD, CEO of Peptilogics, said in the release. “We are delighted that the FDA has granted PLG0206 [qualified infection disease product] QIDP designation, and we look forward to advancing the compound into clinical development later this year.”

Reference:

www.peptilogics.com/single-post/2018/06/01/Peptilogics-Receives-Qualified-Infectious-Disease-Product-Designation-from-FDA-for-Lead-Compound-PLG0206-as-a-Treatment-for-Prosthetic-Joint-Infection

Peptilogics announced the FDA granted qualified infection disease product designation to PLG0206 for the treatment of prosthetic joint infections.

Developed utilizing the company’s engineered cationic antibiotic peptide platform, PLG0206 has been shown in a preclinical study to eliminate a variety of biofilm-associated bacteria, sterilizing implants following short exposure in a biofilm model, according to a company press release. The release noted that these results suggest that, in a clinical setting, PLG0206 may rapidly kill implant-associated biofilm bacteria.

“Researchers estimate that by 2020, more than 65,000 patients per year with prosthetic joint implants will develop [prosthetic joint infections] PJIs, resulting in over $1.6 billion in annual inpatient costs,” Sanjay Kakkar, MD, CEO of Peptilogics, said in the release. “We are delighted that the FDA has granted PLG0206 [qualified infection disease product] QIDP designation, and we look forward to advancing the compound into clinical development later this year.”

Reference:

www.peptilogics.com/single-post/2018/06/01/Peptilogics-Receives-Qualified-Infectious-Disease-Product-Designation-from-FDA-for-Lead-Compound-PLG0206-as-a-Treatment-for-Prosthetic-Joint-Infection